108 reports of this reaction
1.8% of all PREDNISOLONE SODIUM PHOSPHATE reports
#7 most reported adverse reaction
HYPERSENSITIVITY is the #7 most commonly reported adverse reaction for PREDNISOLONE SODIUM PHOSPHATE, manufactured by Advanz Pharma (US) Corp.. There are 108 FDA adverse event reports linking PREDNISOLONE SODIUM PHOSPHATE to HYPERSENSITIVITY. This represents approximately 1.8% of all 5,859 adverse event reports for this drug.
Patients taking PREDNISOLONE SODIUM PHOSPHATE who experience hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERSENSITIVITY is a less commonly reported adverse event for PREDNISOLONE SODIUM PHOSPHATE, but still significant enough to appear in the safety profile.
In addition to hypersensitivity, the following adverse reactions have been reported for PREDNISOLONE SODIUM PHOSPHATE:
The following drugs have also been linked to hypersensitivity in FDA adverse event reports:
HYPERSENSITIVITY has been reported as an adverse event in 108 FDA reports for PREDNISOLONE SODIUM PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERSENSITIVITY accounts for approximately 1.8% of all adverse event reports for PREDNISOLONE SODIUM PHOSPHATE, making it a notable side effect.
If you experience hypersensitivity while taking PREDNISOLONE SODIUM PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.